申请人:Otsuka Pharmaceutical Co., Ltd.
公开号:US04277479A1
公开(公告)日:1981-07-07
Novel tetrazolylalkoxycarbostyril derivative of the formula (I): ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group, a low alkenyl group, a lower alkanoyl group, a benzoyl group or phenylalkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group or a group of the formula ##STR2## R.sup.3 is a lower alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a phenyl group or a phenylalkyl group; A is a lower alkylene group; the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is either single or double bond; and the substituted position of a group of the formula, ##STR3## in the carbostyril skeleton is either 4-, 5-, 6-, 7- or 8-position provided that the only one such group of the formula can be substituted in the whole carbostyril skeleton, thus when R.sup.2 in 4-position is a group of the formula ##STR4## then 5-, 6-, 7- or 8-position will have no such substituted group; furthermore, the phenyl group in the above-mentioned benzoyl group, phenylalkyl group or phenyl group may have substituted group(s). The above-mentioned novel tetrazolylalkoxycarbostyril derivatives have pharmacological activities such as platelet aggregation inhibitory action, antiinflammatory action, antiulcer action, vasodilatory action and phosphodiesterase inhibitory action and are useful as anti-thrombosis agent, cerebral blood flow improving agent, antiinflammatory agent, antiulcer agent, anti-hypertensive agent and anti-asthmatic agent.
化合物的名称为新型四唑基烷氧基卡波斯蒂尔衍生物,其化学式为(I):##STR1## 其中R.sup.1是氢原子,较低的烷基,较低的烯基,较低的酰基,苯甲酰基或苯基烷基;R.sup.2是氢原子,较低的烷基或公式的基团##STR2## R.sup.3是较低的烷基,环烷基,环烷基烷基,苯基或苯基烷基;A是较低的烷基;在卡波斯蒂尔骨架的3-和4-位之间的碳-碳键可能是单键或双键;公式的基团##STR3## 在卡波斯蒂尔骨架中的取代位置可以是4-、5-、6-、7-或8-位,只有一个这样的公式基团可以取代整个卡波斯蒂尔骨架,因此当4-位的R.sup.2是公式的基团##STR4## 时,5-、6-、7-或8-位将没有这样的取代基团;此外,上述苯甲酰基,苯基烷基或苯基中的苯基可能有取代基团。上述新型四唑基烷氧基卡波斯蒂尔衍生物具有药理活性,如抑制血小板聚集作用,抗炎作用,抗溃疡作用,扩血管作用和磷酸二酯酶抑制作用,并可用作抗血栓剂,改善脑血流剂,抗炎剂,抗溃疡剂,降压剂和抗哮喘剂。